Publications by authors named "Luis Matamala"

Claim this Profile
H
Histopathologic Diagnostic Agreement Study in Bone and Soft Tissue Tumors: The SELNET Sarcoma Network Experience.
Alberto Righi, Marco Gambarotti, Rafael Ramos, Rodolfo Guzman, Carmen Nieves Hernandez-Leon, Luis Matamala

JCO Glob Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update.
Evan J Lipson, F Stephen Hodi, Hussein Tawbi, Dirk Schadendorf, Paolo A Ascierto, Luis Matamala

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, Dirk Schadendorf, Paolo A Ascierto, Luis Matamala

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
Georgina V Long, F Stephen Hodi, Evan J Lipson, Dirk Schadendorf, Paolo A Ascierto, Luis Matamala

NEJM Evid· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, Paolo A Ascierto, Luis Matamala

N Engl J Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety.
Luis Villanueva, Jaime Anabalon, Jean M Butte, Pamela Salman, Sergio Panay, Luis Matamala

Ecancermedicalscience· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
and founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile.
Carolina Alvarez, Teresa Tapia, Elisa Perez-Moreno, Patricia Gajardo-Meneses, Catalina Ruiz, Luis Matamala

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis